Skip to content

Effects of whey protein supplementation on gut permeability following exercise

Effects of whey protein supplementation on exercise-induced increases in gut permeability

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN10822766
Enrollment
12
Registered
2025-02-05
Start date
2025-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exercise-induced increases in gut permeability Digestive System

Interventions

1. Trial whey protein concentrate 2. Placebo (also whey-based protein) Treatments will be administered using a randomised, double-blind design. Participants will consume 40 g of their assigned protei

Sponsors

University of Kent
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Male or female 2. 18-65 years old

Exclusion criteria

Exclusion criteria: 1. Disease of the GI tract 2. Renal, hepatic, endocrine (including diabetes mellitus), cardiac, pulmonary, pancreatic, neurologic or biliary disorders 3. Intolerance or any known or suspected hypersensitivity (allergy) to study products/ingredients 4. Recent use of antibiotics (within 1 month of study) 5. Current, or recent, use of certain medications (NSAIDs) 6. Current, or recent, use of certain supplements (as per the researcher's determination) that could influence study measures or outcomes (such as pre or probiotics, for example) 6. Females who are pregnant, lactating, or planning to become pregnant during the study period 7. Enrolment in any other similar trial within 3 months prior to recruitment 8. Investigator's determination of unsuitability for trial participation

Design outcomes

Primary

MeasureTime frame
Lactulose:rhamnose ratio will be measured in urine samples taken at baseline (pre-supplementation) and post-exercise on main trials

Secondary

MeasureTime frame
1. Intestinal fatty-acid binding protein (I-FABP) will be measured by ELISA assays in blood samples taken pre-, post- and +1 h post-exercise 2. Bacterial load will be measured by qPCR on blood samples taken pre-, post- and +1 h post-exercise 3. Soluble CD14 (sCD14) concentration will be measured by ELISA assays in blood samples taken pre-, post- and +1 h post-exercise 4. WBC differentiation will be immediately performed on whole blood samples taken pre-, post- and 1-h post-exercise on main trial days

Countries

England, United Kingdom

Contacts

Public ContactWilliam Searle
W.J.Searle@ljmu.ac.uk-

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jul 3, 2026